<i>In vivo</i> experiments further confirmed these effects.<h4>Conclusion</h4>C1orf112 contributes to breast cancer progression in association with cell cycle pathways, making it a potential diagnostic and therapeutic target with clinical applications. Here, FIRRM is linked to breast cancer.